Skip to Content

DexCom Inc DXCM Stock Quote

| Rating as of


Last close prices updated as of Jun 02, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 119.58
  • Sector Healthcare
  • Industry Medical Devices
  • Investment Style Large Growth
  • Day Range 118.68  –  122.84
  • Year Range 67.11  –  126.44
  • Market Cap 47.5125 Bil
  • Volume / Avg 2.7 Mil /  2.3 Mil
  • Price / Sales 16.81
  • Price / Book 20.76
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis DXCM

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Dexcom Earnings: Favorable Reimbursement Developments Brighten Prospects for G7

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie Wang |

Dexcom delivered a strong start to 2023 with first-quarter organic revenue growth of 19% year over year. Considering the firm is on track with our full-year estimates and our projections remain bounded by management’s increased revenue outlook for 2023, we’re holding steady on our fair value estimate. Now that Dexcom has navigated heightened competition from Abbott and Medtronic, and has managed to stay in the black through the pandemic, we can see an argument for awarding Dexcom a narrow moat. We plan to revisit our thinking on this shortly.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DXCM

Company Profile DXCM

Business Description

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem.

6340 Sequence Drive
San Diego, CA, 92121
Industry Medical Devices
Employees 1,061

Related Articles DXCM

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of DXCM’s competitive advantage.

DexCom Inc


Abbott Laboratories


Medtronic PLC


Insulet Corp

+$2.99 (2.50%) +$1.38 (1.34%) +$1.01 (1.22%) +$8.55 (3.14%)
Market Cap
47.51 Bil181.20 Bil111.47 Bil19.59 Bil
Medical Devices Medical Devices Medical Devices Medical Devices

* Trading data in this section is delayed by at least 15 minutes.

FAQs for DexCom Inc Stock

No. DXCM does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

DXCM’s market cap is 47.51 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

DXCM’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

DXCM’s price/sales is 16.81.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

DXCM’s price/forward earnings is 170.83.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

DXCM’s price/book is 20.76.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See DXCM’s valuation ratios compared to the Market Index.

DXCM’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare DXCM’s historical performance against its industry peers and the overall market.